ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months but have fewer side effects — according to study findings announced at the 2013 ASCO Genitourinary Cancers Symposium in Orlando by Dr Abdenour Nabid from Sherbrooke University in Quebec.
You may also like...
Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer 16 Nov, 2007 Early Lung Cancer Responds to Preoperative Nivolumab 17 Nov, 2016 Polygenic Risk Scores Could Help Predict Second Primary Breast Cancers—AUDIO JOURNAL OF ONCOLOGY 28 Mar, 2018 Tumour heterogeneity — clonal evolution of cancer limits effectiveness of targeted systemic therapies 26 Mar, 2014
- Previous story MDFM News: Overview of the 2nd World Summit on Gut Microbiota (section of the European Society of Neurogastroenterology and Motility)
- Next story Low risk prostate cancer: less treatment means lower cost, and better patient outcomes
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014